SEMARION
Semarion is a spin-out company from the Cavendish Laboratory at the University of Cambridge, operating at the edge of the physical and life sciences. Semarion combines microchip industry materials and techniques engineering and cell biology to tackle unmet drug screening needs.
SEMARION
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Cambridge, Cambridgeshire, United Kingdom
Country:
United Kingdom
Website Url:
http://www.semarion.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.39 M GBP
Investors List
Parkwalk Advisors
Parkwalk Advisors investment in Seed Round - Semarion
Martlet Capital
Martlet Capital investment in Seed Round - Semarion
University of Cambridge Enterprise
University of Cambridge Enterprise investment in Seed Round - Semarion
Start Codon
Start Codon investment in Pre Seed Round - Semarion
Official Site Inspections
http://www.semarion.com Semrush global rank: 6.9 M Semrush visits lastest month: 708
- Host name: 18.133.230.35.bc.googleusercontent.com
- IP address: 35.230.133.18
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Semarion"
About - Semarion
Semarion is building a technology platform that revolutionizes in vitro research on cell models to help create better medicines, faster. Team. About Jeroen . Jeroen drives the strategic deployment of Semarion’s cell assaying solutions across …See details»
Semarion - Crunchbase Company Profile & Funding
Organization. Semarion . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. About. ... Semarion is a …See details»
Careers - Semarion
At Semarion you will always be encouraged to pursue your ideas and think beyond your expertise. Together, we make sure to foster personal development and general well-being. Benefits of working at Semarion. Flexible working. …See details»
Semarion Ltd. | Lab Manager
Mar 20, 2024 Semarion Ltd. Semarion is built on fostering collaboration across disciplines to tackle foundational bottlenecks in drug discovery. We operate at the edge of the physical and …See details»
Semarion - LinkedIn
Semarion is a spin-out from Cambridge University with a mission to accelerate the pace of drug discovery. We are revolutionising adherent cell screening to produce better data, faster.See details»
Semarion Company Profile 2024: Valuation, Funding & Investors
Semarion General Information Description. Developer of a drug discovery and cell microcarrier platform designed to revolutionize adherent cell screening to accelerate the pace of drug …See details»
Semarion Company Profile - Office Locations, Competitors ... - Craft
Semarion has 5 employees at their 1 location and $3.53 m in total funding,. See insights on Semarion including office locations, competitors, revenue, financials, executives, subsidiaries …See details»
Semarion - 2022 - Wiley Analytical Science
Mar 7, 2022 Innovating Across Disciplines: Semarion is built on fostering collaboration across disciplines to tackle foundational bottlenecks in drug discovery. The company operates at the …See details»
Semarion - Funding, Financials, Valuation & Investors - Crunchbase
Feb 22, 2022 Semarion leverages microfabrication technology to build smart materials and develop novel cell assaying applications. Search Crunchbase. Start Free Trial . ... How much …See details»
Semarion | VentureRadar
Semarion is an early-stage drug screening and lead identification company focussed on the discovery of first-in-class, GPCR-targeting oncology drugs. Our SemaCyte Platform, …See details»
Semarion LTD | Scientist.com
Semarion’s SemaCyte® microcarrier platform leverages novel materials physics to barcode, move, and freeze adherent cells within assaying workflows. This innovative solution introduces …See details»
Semarion | Semarion Introduces SemaCyte Multiplexing Platform …
Mar 20, 2024 Dr. Del Trezise, Advisor and Non-Executive Director, Semarion, said: “The SemaCyte Multiplexing Platform has been specifically designed to address the limitations of …See details»
Semarion Raises £2.14 Million GBP ($2.89 Million USD) Seed Funding
Feb 22, 2022 Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unme Semarion Raises …See details»
Semarion Introduces SemaCyte Multiplexing Platform to Enhance …
CAMBRIDGE, England, March 20, 2024--Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to …See details»
Semarion | Semarion raises £2.14m seed funding to commercialise …
Feb 22, 2022 Semarion raises £2.14 million GBP ($2.89 million USD) seed funding. Funding will support recruitment, commercial partnerships, and further development of Semarion’s …See details»
Semarion Careers, Perks + Culture - Built In
Semarion is a spin-out from Cambridge University with a mission to accelerate the pace of drug discovery. We are revolutionising adherent cell screening to produce better data, faster. Our …See details»
Semarion | VentureRadar
Metrion Biosciences United Kingdom Privately Held Metrion Biosciences is a UK-based Contract Research Organization (CRO) focussed on delivering a range of high quality ion channel drug …See details»
Semarion - Start Codon
Semarion was spun out of the University of Cambridge by Start Codon and has since received follow on funding by Parkwalk, the University of Cambrige, Marlet Capital and Vincent …See details»
News - Semarion
Mar 20, 2024 Semarion is excited about attending On Helix 2020. Connect with our CEO Jeroen Verheyen or CTO Tarun Vemulkar if you are there. Jeroen will and speaking during the "Rising …See details»